Antimicrobial evidence becomes the market-access test for Brazilian beef

From 3 September 2026, European requirements on the use of certain antimicrobials will be explicitly linked to market access for certain animals and foods of animal origin from third countries. According to Fleisch & Co, Brazil has not yet provided the guarantees required for beef. This is not about an analytical result from an individual consignment, but about binding proof that EU restrictions are met throughout the supply chain serving Europe.

That changes the commercial meaning of documentation. For producers, slaughterhouses, exporters and importers, the issue is no longer merely whether rules for medicinal use exist. It must be possible to demonstrate, consistently and verifiably, which rules apply, what data support them and which products they relate to. If that assurance is missing, even physically compliant goods can lose market access.

The development matters to European buyers beyond Brazil. Alternative raw materials do not enter procurement automatically: they must meet sanitary, veterinary, logistical and contractual requirements and be able to prove it. In beef, production lead times, supplier approvals and cutting specifications make it difficult to replace volumes at short notice. Procurement should therefore distinguish between availability risk, price risk and compliance risk.

The lesson for meat chains is clear: traceability is no longer only a promise of origin; it becomes market-access infrastructure. Businesses that can reliably link medicinal-use data, farms, batches and customers reduce commercial uncertainty. In sales and communication, it is equally important to distinguish precisely between a regulatory access risk and a general assessment of product quality or safety.